{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:26:47Z","timestamp":1790008007949,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.tvjl.2013.08.003","type":"journal-article","created":{"date-parts":[[2013,8,10]],"date-time":"2013-08-10T23:45:17Z","timestamp":1376178317000},"page":"577-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo"],"prefix":"10.1016","volume":"198","author":[{"given":"Keita","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tetsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyo","family":"Hiroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukimi","family":"Washizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Bonkobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2013.08.003_b0005","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2403460","article-title":"Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas","volume":"18","author":"An","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.tvjl.2013.08.003_b0010","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.tvjl.2013.08.003_b0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: The first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.tvjl.2013.08.003_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00480169.2012.699433","article-title":"Malignant melanoma in 63 dogs (2001\u20132011): The effect of carboplatin chemotherapy on survival","volume":"61","author":"Brockley","year":"2012","journal-title":"New Zealand Veterinary Journal"},{"key":"10.1016\/j.tvjl.2013.08.003_b0025","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.tvjl.2013.08.003_b0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tvjl.2013.08.003_b0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tvjl.2012.09.005","article-title":"KIT gene exon 11 mutations in canine malignant melanoma","volume":"192","author":"Chu","year":"2013","journal-title":"The Veterinary Journal"},{"key":"10.1016\/j.tvjl.2013.08.003_b0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.11666","article-title":"The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype","volume":"93","author":"Colado","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.tvjl.2013.08.003_b0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401881","article-title":"Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells","volume":"13","author":"Coquelle","year":"2006","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.tvjl.2013.08.003_b0050","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0055","article-title":"Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision","author":"Dank","year":"2013","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0060","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.tvjl.2013.08.003_b0065","first-page":"96","article-title":"Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987\u20131997)","volume":"17","author":"Freeman","year":"2003","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2013.08.003_b0070","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0075","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2013.08.003_b0080","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2013.08.003_b0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1939-1676.2008.00132.x","article-title":"Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs","volume":"22","author":"Isotani","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2013.08.003_b0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2141.2009.07926.x","article-title":"Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours","volume":"148","author":"Isotani","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd1279","article-title":"The IKK NF-kappa B system: A treasure trove for drug development","volume":"3","author":"Karin","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.tvjl.2013.08.003_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2011.192","article-title":"Tumor control versus adverse events with targeted anticancer therapies","volume":"9","author":"Keefe","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0110","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1292\/jvms.12-0168","article-title":"Analyses on activation of NF-\u03baB and effect of bortezomib in canine neoplastic lymphoid cell lines","volume":"75","author":"Kojima","year":"2013","journal-title":"Journal of Veterinary Medical Science"},{"key":"10.1016\/j.tvjl.2013.08.003_b0115","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2013.08.003_b0120","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1158\/1535-7163.MCT-08-0391","article-title":"Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway","volume":"7","author":"Lioni","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.tvjl.2013.08.003_b0125","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.tvjl.2013.08.003_b0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/j.tvjl.2013.08.003_b0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1476-5829.2010.00253.x","article-title":"Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas","volume":"9","author":"Murakami","year":"2011","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1476-5810.2005.00082.x","article-title":"Oral malignant melanoma \u2013 The effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy","volume":"3","author":"Murphy","year":"2005","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tvjl.2013.08.003_b0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1740-8261.2003.tb00468.x","article-title":"A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation","volume":"44","author":"Proulx","year":"2003","journal-title":"Veterinary Radiology and Ultrasound"},{"key":"10.1016\/j.tvjl.2013.08.003_b0160","doi-asserted-by":"crossref","first-page":"9636","DOI":"10.1158\/0008-5472.CAN-06-0747","article-title":"Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA","volume":"66","author":"Qin","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2013.08.003_b0165","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","article-title":"Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989\u20132000)","volume":"218","author":"Rassnick","year":"2001","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2013.08.003_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00335-004-2441-x","article-title":"Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas","volume":"16","author":"Shelly","year":"2005","journal-title":"Mammalian Genome"},{"key":"10.1016\/j.tvjl.2013.08.003_b0180","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1354\/vp.39-6-651","article-title":"A comparative review of melanocytic neoplasms","volume":"39","author":"Smith","year":"2002","journal-title":"Veterinary Pathology"},{"key":"10.1016\/j.tvjl.2013.08.003_b0185","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1158\/1535-7163.MCT-09-0239","article-title":"The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models","volume":"8","author":"Williamson","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.tvjl.2013.08.003_b0190","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-09-0459","article-title":"Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates","volume":"8","author":"Woodman","year":"2009","journal-title":"Molecular Cancer Therapeutics"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002331300378X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002331300378X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:27:20Z","timestamp":1761071240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109002331300378X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S109002331300378X"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2013.08.003","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2013.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}